The Biden administration on Oct. 21 issued a new proposed rule that would require health insurance providers to cover an ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...
GlobalData on MSN2d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...
The measure waives the need for a primary care physician’s prescription for HIV medications like PrEP and Doxy PEP.
News Medical on MSN2d
Affordability and supply remain critical to the success of long-lasting HIV drugAffordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...
With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...
Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...
Pre-exposure prophylaxis (PrEP) with antiretroviral medications is effective in preventing HIV infections. PrEP use has increased between 2013 and 2023. Multiple PrEP medications are available in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback